Dr. Kuerer plays a leading role in MD Anderson’s world-renowned breast care group as a recognized cancer surgeon and researcher who specializes in the multidisciplinary care of patients with breast cancer. Recruited back to MD Anderson to help establish a premier program to train breast cancer surgeons of the future, he became the founding Director of the Breast Surgical Oncology Training Program and is now the Executive Director of the MD Anderson Cancer Network Breast Programs. He maintains a busy clinical research program and has been heavily involved with the Alliance for Clinical Trials in Oncology and the national cooperative group: NRG Oncology. He has been a pioneer in breast cancer research and treatments that have led to clinical practice changes in oncology serving as the developer and clinical trial Principal Investigator for a new surgical oncology procedure called “Targeted Axillary Dissection” or TAD that has been internationally adopted to spare patients from extensive axillary surgery after neoadjuvant systemic therapy when disease was initially present in the lymph nodes. He is also leading a groundbreaking clinical trial that is testing elimination of breast cancer surgery utilizing state-of-the-art image guided biopsy selection for patients who have a complete response to neoadjuvant systemic therapy. Dr. Kuerer is heavily involved with the MD Anderson Cancer Network clinical expansion in terms of comprehensive assessment, benchmarking, and review of potential new partners and ongoing member hospital and programmatic relationships nationally and internationally. Dr. Kuerer is a recognized authority in breast cancer treatments and regularly invited speaker at academic, national, and international meetings and has authored or coauthored more than 500 peer-reviewed scientific reports, editorials/commentaries, and text chapters. Dr. Kuerer is Editor-in-Chief of the definitive McGraw-Hill textbook, Breast Surgical Oncology.